Find policies, billing codes, payers, states, and providers
CPT 80305: Presumptive Drug Test by Visual Read
CPT code 80305 covers presumptive drug screening tests visually read by a laboratory analyst without instrument assistance. These manual, point-of-care style assays are used to rapidly screen for one or multiple drug classes on a single date and are widely used across clinical laboratories, outpatient clinics, and urgent care settings. The code matters nationally because it represents a common, low-complexity screening service that intersects clinical workflows, laboratory operations, and payer coverage policies.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code denotes, the typical service setting, and how it is categorized for billing. The publication provides benchmarks and payer policy considerations relevant to reimbursement and claims processing for manual presumptive drug tests, plus clinical context on when visually read screenings are used versus instrumented testing.
This summary is designed to help billing managers, laboratory administrators, and policy analysts understand the clinical purpose of CPT code 80305, the payer landscape, and the operational contexts where the code is applied. Data not available in the input will be noted where applicable.
Customize your policy alerts
Sign up for cpt 80305 policy alerts
Get alerted when payer policies referencing 80305 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 80305 describes a presumptive drug test by direct optical observation, performed by a laboratory analyst. The analyst reads test results visually without instrument assistance to screen for one or more drug classes on a single date.
Service Type: Laboratory — Point-of-Care/Manual Presumptive Drug Screening
Typical Site of Service: Clinical laboratory, point-of-care locations such as outpatient clinics, urgent care centers, or other settings where manual drug screening is performed
Data not available in the input.
National Reimbursement Benchmarks
For CPT 80305, BUCA’s average commercial rate sits at $39.7, serving as a useful midpoint for national commercial pricing. Blue Cross Blue Shield has the highest variability with a P75–P25 spread of $34.5 ($72.8 − $37.3), driven by a wide top-end maximum of $295.4 that pulls the mean above most peers. Aetna and Cigna exhibit similar central tendencies near the low teens, while UnitedHealth Group’s median of $7.6 is notably lower than its peers’ medians.
Assessing dispersion shows UnitedHealth Group and Aetna have the tightest interquartile ranges: UnitedHealth Group’s P75–P25 is $7.0 ($12.6 − $5.6) and Aetna’s is $6.0 ($15.0 − $9.0), indicating more compressed commercial pricing. Blue Cross Blue Shield is the widest at $34.5, with Cigna and BUCA in between (Cigna IQR $8.4; BUCA IQR $21.2), highlighting material differences in commercial rate concentration across payers.